6-(1,5-dioxa-9-aza-spiro[5.5]undec-9-yl)-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide | 1021683-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 6-(1,5-dioxa-9-aza-spiro[5.5]undec-9-yl)-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide
• 英文别名: 4-chloro-N-[6-(1,5-dioxa-9-azaspiro[5.5]undecan-9-yl)pyridin-3-yl]sulfonyl-2-methoxybenzamide
• CAS: 1021683-10-2
• 化学式: C₂₁H₂₄ClN₃O₆S
• 分子量: 481.957
• InChiKey: FIYKRPQHDLIVRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
  申请人：Brookfield Frederick

  公开号：US20100292247A1

  公开（公告）日：2010-11-18

  Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式I的化合物，它们的药学上可接受的盐，对映体形式，非对映异构体和混合物，上述化合物的制备，包含它们的药物以及它们的制造方法，以及上述化合物在控制或预防癌症等疾病方面的应用。
• US7939532B2
  申请人：——

  公开号：US7939532B2

  公开（公告）日：2011-05-10
• [EN] HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] DÉRIVÉS D'HÉTÉROCYCLYL PYRIDYL SULFONAMIDE, LEUR FABRICATION ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008049605A1

  公开（公告）日：2008-05-02

  [EN] Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
  [FR] La présente invention concerne des composés de formule (I) [Formule (I)], leurs sels, leurs formes énantiomères, leurs diastéréoisomères et leurs racémates pharmaceutiquement acceptables, la préparation des composés ci-dessus, des médicaments qui les contiennent et leur fabrication, de même que l'utilisation des composés ci-dessus pour le traitement ou la prévention de maladies telles que le cancer.